Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Dergham, S T; Dugan, M C; Kucway, R; Du, W; Kamarauskiene, D S; Vaitkevicius, V K; Crissman, J D; Sarkar, F H

Dergham, S T; Dugan, M C; Kucway, R; Du, W; Kamarauskiene, D S; Vaitkevicius, V K; Crissman, J D; Sarkar, F H.

Affiliation

Dergham ST; Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Int J Pancreatol ; 21(2): 127-43, 1997 Apr.

Article in En | MEDLINE | ID: mdl-9209954

Subject(s)

Adenocarcinoma/genetics; Genes, p53; Genes, ras; Mutation; Pancreatic Neoplasms/genetics; Adenocarcinoma/mortality; Adenocarcinoma/therapy; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Primers/genetics; Female; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms/mortality; Pancreatic Neoplasms/therapy; Prognosis; Survival Rate; Tumor Suppressor Protein p53/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Genes, p53 / Genes, ras / Mutation Type of study: Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Int J Pancreatol Journal subject: GASTROENTEROLOGIA Year: 1997 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links